Severe Persistent Cerebellar Dysfunction Complicating Cytosine Arabinoside Therapy
- 12 January 1988
- journal article
- case report
- Published by Wiley in Acta Medica Scandinavica
- Vol. 224 (2) , 189-191
- https://doi.org/10.1111/j.0954-6820.1988.tb16760.x
Abstract
A case of persistent cerebellar dysfunction following high‐dose cytosine arabinoside (Ara‐C) treatment of acute myelogeneous leukemia is reported. The symptoms developed after a cumulative dose of 24 g/m2, and 6 months after the start of symptoms, the signs of cerebellar damage were unchanged. The symptoms aggravated during a subsequent low‐dose therapy with Ara‐C, 15 mg twice daily. This supports the presumption that this adverse effect is caused by the cumulative dose rather than by high plasma concentrations.Keywords
This publication has 15 references indexed in Scilit:
- Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemiaThe American Journal of Medicine, 1986
- Treatment-Related LeukoencephalopathyMedicine, 1986
- Cerebellar dysfunction during high dose cytosine arabinoside therapy in a case of acute myelogenous leukaemiaScandinavian Journal of Haematology, 1986
- Central nervous system toxicity with high‐dose Ara‐CNeurology, 1985
- Acute cerebellar dysfunction with high-dose ARA-C therapyCancer, 1983
- Therapy of Secondary Acute Nonlymphocytic Leukemia with CytarabineNew England Journal of Medicine, 1983
- High Dose Cytosine Arabinoside in the Management of Refractory Acute LeukaemiaScandinavian Journal of Haematology, 1982
- Effect of schedule and combinations on clinical effectiveness of Ara-C in adult acute leukemiaMedical and Pediatric Oncology, 1982
- Central nervous system toxicity of high-dose systemic cytosine arabinosideCancer, 1981
- Cerebellar Degeneration With Hodgkin DiseaseArchives of Neurology, 1976